[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Novo-Nordisk (NVO)

Novo Nordisk's stock shows signs of a potential bottom, boosted by positive sentiment on capital discipline and share buybacks, alongside promising trial results for Amycretin. However, concerns about competition and market share persist.

About Novo-Nordisk

Novo Nordisk is a pharmaceutical company specializing in diabetes and obesity treatments.
Novo-Nordisk uses the ticker $NVO for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Novo-Nordisk (NVO) trading volume is up XXXXX% from the previous week.
Novo-Nordisk (NVO) social dominance is up XXXX% from the previous week.
Novo-Nordisk (NVO) Galaxy Score™ is up XX% from the previous week.

Price: $XXXXX

Price 24-Hour Time-Series Raw Data
The stock price is showing signs of a potential bottom, influenced by positive social sentiment regarding capital discipline and potential share buybacks, alongside recent positive trial results for Amycretin, despite concerns about competition and market share.

24-Hour: XXXX% 7-Day: XXXX% 30-Day: XXXX%

1-Year High: $XXXXXX on 2024-12-12
1-Year Low: $XX on 2025-11-24

AltRank: XXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Novo-Nordisk (NVO) is currently AltRank #299 based on combined combined social and market metrics Daily Average: XXX
X Week: XXX -XX
X Month: XXX -XXX
X Months: XXX -XXX
X Year: XXX -XX
1-Year High: XXXXX on 2025-07-17
1-Year Low: X on 2025-06-10

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +15
X Month: XX no change
X Months: XX +34
X Year: XX +24
1-Year High: XX on 2025-06-10
1-Year Low: XX on 2025-01-03

Engagements: XXXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXXX
Daily Average: XXXXXXX
X Week: XXXXXXXXX -XX%
X Month: XXXXXXXXXX -XX%
X Months: XXXXXXXXXXX +117%
X Year: XXXXXXXXXXX +212%
1-Year High: XXXXXXXXX on 2025-11-02
1-Year Low: XXXXXX on 2025-01-05

Engagements by network (24h): Reddit: XXXXX TikTok: XXXXX X: XXXXXXX YouTube: XXXXX

Mentions: XXXXX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
X Week: XXXXX -XX%
X Month: XXXXXX -XXXX%
X Months: XXXXXX +87%
X Year: XXXXXX +129%
1-Year High: XXXXX on 2025-11-07
1-Year Low: XXX on 2025-03-01

Mentions by network (24h): Reddit: XXX TikTok: XXX X: XXXXX YouTube: XX

Creators: XXX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XXX unique social accounts have posts mentioning Novo-Nordisk (NVO) in the last XX hours which is up XX% from XXX in the previous XX hours Daily Average: XXX
X Week: XXXXX -XX%
X Month: XXXXX -XXXX%
X Months: XXXXXX +112%
X Year: XXXXXX +147%
1-Year High: XXXXX on 2025-11-07
1-Year Low: XXX on 2025-01-27

The most influential creators that mention Novo-Nordisk in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@TheLongInvest	X	XXXXXXX	X	XXXXXX
@himshouse	X	XXXXXX	X	XXXXXX
@Nebraskangooner	X	XXXXXXX	X	XXXXXX
@Mr_Derivatives	X	XXXXXXX	X	XXXXXX
@GilaMonstrum	X	XXXXX	X	XXXXXX
@investseekers	X	XXXXX	XX	XXXXXX
@TacticzH	X	XXXXXX	XX	XXXXXX
@ValueSense_io	X	XXXXXX	XX	XXXXXX
@DeepIceValue	X	XXXXXX	XX	XXXXXX
@pdicarlotrader	XX	XXXXXX	X	XXXXX

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% +4%
X Month: XX% +4%
X Months: XX% -X%
X Year: XX% +3%
1-Year High: XX% on 2025-11-02
1-Year Low: XX% on 2025-06-23

Most Supportive Themes:

Positive Clinical Trial Results and Wegovy's Cardiovascular Benefits: (35%) Posts highlighting positive results from clinical trials for Novo Nordisk's drugs, particularly Wegovy, and its cardiovascular benefits.
Long-Term Growth Potential and Valuation: (25%) Posts discussing the long-term growth potential of Novo Nordisk, especially in the obesity and diabetes markets, and its current valuation.
Expert Analysis and Recommendations: (15%) Posts from analysts and financial experts recommending Novo Nordisk as a buy or highlighting its strengths.

Most Critical Themes:

Competition and Market Share Concerns: (20%) Posts expressing concerns about increasing competition from other pharmaceutical companies, particularly Eli Lilly, and its impact on Novo Nordisk's market share.
Negative Guidance and Restructuring: (5%) Posts discussing the company's lowered sales and operating profit outlook, job cuts, and restructuring efforts.

Social Dominance: XXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.145%
X Month: XXXXX% -XXXXX%
X Months: XXXXX% +0.135%
X Year: XXXXX% +0.097%
1-Year High: XXXXX% on 2024-12-22
1-Year Low: XXXX% on 2025-03-23

Market Dominance: XXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-03-31
1-Year Low: XXXXX% on 2025-11-10

Market Cap: $XXXXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXXX +$4.40%
X Month: $XXXXXXXXXXXXXXX +$2.20%
X Months: $XXXXXXXXXXXXXXX -$37%
X Year: $XXXXXXXXXXXXXXX -$55%
1-Year High: $XXXXXXXXXXXXXXX on 2024-12-12
1-Year Low: $XXXXXXXXXXXXXXX on 2025-11-24